1. GPCR/G Protein
  2. Adenosine Receptor
  3. Regadenoson

Regadenoson  (Synonyms: CVT-3146)

Cat. No.: HY-A0168 Purity: 98.35%
COA Handling Instructions

Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS.

For research use only. We do not sell to patients.

Regadenoson Chemical Structure

Regadenoson Chemical Structure

CAS No. : 313348-27-5

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 83 In-stock
Solution
10 mM * 1 mL in DMSO USD 83 In-stock
Solid
2 mg USD 50 In-stock
5 mg USD 75 In-stock
10 mg USD 115 In-stock
25 mg USD 225 In-stock
50 mg USD 348 In-stock
100 mg USD 530 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Regadenoson:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].

In Vivo

Regadenoson (0.1, 0.175, 0.25, 0.5, 1.0, 2.5, 5 μg/kg; p.i.v.; single) increases coronary blood flow (CBF) and decreases in mean coronary resistance in a dose-dependent manner, in awake dogs[1].
? Regadenoson (2.5 μg/kg; p.i.v.; single in 30 s) increases blood flow of coronary in awake dogs[1].
? Regadenoson (0.5 μg/kg; i.v.; single; 60 or 90 min after Temozolomide administration) promotes Temozolomide delivery to CNS of rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mongrel dogs (23-27 kg)[1]
Dosage: 0.1, 0.175, 0.25, 0.5, 1.0, 2.5, 5 µg/kg
Administration: Peripheral intravenous injection; single.
Result: Increased mean CBF (coronary blood flow) in a dose-dependent manner, with an ED50 of 0.34 µg/kg and resulted in a maximal increase of 154 mL/min from baseline (45 mL/min).
Caused a dose-dependent decrease in mean coronary resistance with a maximal decrease of 73 and 75 % at 2.5 and 5 µg/kg, respectively.
Animal Model: Mongrel dogs (23-27 kg)[1]
Dosage: 2.5 µg/kg
Administration: Peripheral intravenous injection; single in 30 s.
Result: Reached 84% of the peak reactive hyperemia flow following a 20-s-long coronary occlusion (201 mL/min).
Animal Model: Female F344 rats (150-170 g)[2]
Dosage: 0.5 µg/kg
Administration: Intravenous injection; single (60 or 90 min after Temozolomide administration)
Result: Increaseed levels of Temozolomide by 60 % in normal brain without affecting plasma concentrations.
Clinical Trial
Molecular Weight

390.35

Appearance

Solid

Formula

C15H18N8O5

CAS No.
SMILES

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(N=C2)C(N)=NC(N4C=C(C=N4)C(NC)=O)=N3)O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (128.09 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5618 mL 12.8090 mL 25.6180 mL
5 mM 0.5124 mL 2.5618 mL 5.1236 mL
10 mM 0.2562 mL 1.2809 mL 2.5618 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Regadenoson Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Regadenoson
Cat. No.:
HY-A0168
Quantity:
MCE Japan Authorized Agent: